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Abstract
Simulation offers a simple and flexible way to estimate the power of a clinical trial when analytic formulae are not
available. The computational burden of using simulation has, however, restricted its application to only the simplest of
sample size determination problems, often minimising a single parameter (the overall sample size) subject to power
being above a target level. We describe a general framework for solving simulation-based sample size determination
problems with several design parameters over which to optimise and several conflicting criteria to be minimised. The
method is based on an established global optimisation algorithm widely used in the design and analysis of computer
experiments, using a non-parametric regression model as an approximation of the true underlying power function. The
method is flexible, can be used for almost any problem for which power can be estimated using simulation, and can be
implemented using existing statistical software packages. We illustrate its application to a sample size determination
problem involving complex clustering structures, two primary endpoints and small sample considerations.
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1. Introduction
The sample size of a clinical trial is typically chosen with respect to its power, which is the probability of a
statistically significant result conditional on the parameter of interest being equal to the minimal clinically impor-
tant difference (MCID).1 Since power will generally increase with sample size, a nominal power threshold (often
80% or 90%) is set and the smallest sample size which satisfies this is selected. For many sample size determi-
nation (SSD) problems, power can be calculated using a simple mathematical formula and the optimisation
problem can be solved in a timely manner. When complexity in the trial design or the method of analysis
mean such formulae are not readily available, we can estimate power using a Monte Carlo (MC) approxima-
tion.2,3 To do so, we simply simulate several hypothetical sets of trial data under the alternative hypothesis,
analyse each of these, and calculate the proportion of analyses which reject the null hypothesis. The simplicity and
flexibility of the simulation method has seen it used for a variety of statistical models and study designs, including
problems involving hierarchical models,4,5 proportional hazards models,6 logistic regression models,7 individual
patient data meta-analyses,8 patient enrolment models,9 stepped wedge designs10,11 and cluster randomised cross-
over designs.12 Although calculating MC estimates of power can be computationally demanding, these SSD
problems remain feasible because, as optimisation problems, they are quite simple. In particular, optimisation
1Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK
2Centre for Primary Care & Public Health, Queen Mary University of London, London, UK
Corresponding author:
Duncan T Wilson, Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds LS2 9JT, UK.
Email: d.t.wilson@leeds.ac.uk
Statistical Methods in Medical Research
0(0) 1–17
! The Author(s) 2020
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/0962280220975790
journals.sagepub.com/home/smm
takes place over a single parameter (the sample size), subject to a single constraint (power), and with respect to a
single objective to be minimised (the sample size again).
SSD problems, particularly those found in trials of complex interventions, are not always this simple.13 There
may be several dimensions to the trial’s sample size or, more generally, several quantitative parameters, which
must be specified at the design stage and which influence the power of the trial. We will refer to these as design
parameters. Several design parameters are common in, for example, trials with multilevel structures such as cluster
randomised trials, where both the number of clusters and the number of participants in each cluster must be
specified. Increasing the number of design parameters complicates the SSD problem by increasing the number of
possible solutions to search. A second complication arises when there is more than one criterion we are interested
in minimising, subject to the nominal power constraint. A cluster randomised trial will often have this property, as
we would like to minimise both the total number of participants and the number of clusters. Given multiple
conflicting objectives, there is no single ‘optimum’ solution but rather a range of solutions which offer different
degrees of trade-off between the objectives. Seeking a set of good solutions, rather than a single optimum, further
adds to the difficulty of the SSD problem.
Simple, simulation-based SSD problems can generally be solved in a feasible time with an exhaustive
search,14,15though a bisection search, as proposed by Williams et al.16 and refined by Jung,17 may be more
efficient. A more sophisticated algorithm was implemented in the SimSam package,5 written for Stata (Stata
Corporation, College Station, TX, USA). Although there is no such general framework for solving complex SSD
problems, a number of methods have been proposed for specific applications. In some cases, these methods
impose restrictions which reduce the complex SSD problem to a simple one in a single dimension. For example,
approaches to simulation-based SSD for stepped wedge trials have focused on choosing one design parameter
(such as the number of clusters randomised to each sequence) while keeping others (the number of participants per
cluster and the number and arrangement of sequences) fixed.10,11 In other applications, including meta-analysis,18
work has focussed on estimating power through simulation but has left the associated complex SSD problem
unspecified. The complexity of SSD in multilevel designs has been addressed to some extent in the MLPowSim
package,15 although this is limited to performing a simple grid search over two design variables (the number of
clusters, and the cluster size). Adaptive designs are another area where simulation is often used to estimate
operating characteristics, and where the SSD problem is complex due to the large number of design parameters
needed to describe stopping rules. Where these problems have been addressed, optimisation has remained feasible
through some special structure of the problem being identified and exploited. For example, optimal multi-arm
multi-stage designs can be found when the primary endpoint is normally distributed, since one can draw a single
large sample from a multivariate normal distribution prior to optimisation and use transformations of these
samples over the course of the search.19 Together with an implementation in Cþþ, this leads to feasible compu-
tation times.
In theory, a general approach to solving any complex SSD problem would be through using benchmark multi-
objective optimisation algorithms such as NSGA-II,20 robust implementations of which are freely available in
statistical software such as R.21 However, these so-called ‘greedy’ algorithms typically assume that evaluating any
proposed solution to the problem is a very fast process, and consequently evaluate many thousands of solutions
during the search. If these algorithms were applied to problems where evaluating solutions required computing an
MC estimate of power, they would take an infeasibly long time to converge. Thus, if we are to extend simulation-
based trial design to complex SSD problems, we require a more general framework employing more efficient
optimisation algorithms.
Outwith the context of clinical trial design, a great deal of research has addressed optimisation problems where
the evaluation of a solution is a computationally demanding, or expensive, operation.22,23 One approach addresses
the problem by substituting the expensive function with a mathematical approximation known as a surrogate
model. The surrogate model is then used to make predictions about the true function for different values of design
parameters, with these predictions informing which point should be evaluated next. The information obtained
from this evaluation is used to update the surrogate model, thus improving the predictions available at the next
iteration. One class of surrogate model is Gaussian process (GP) regression. Also known as Kriging and having its
roots in geostatistics,24 GP models are spatial interpolators that are computationally tractable25 and can be fitted
using robust and freely available software.26 A GP surrogate model provides not only a prediction of the true
function value at any point, but also a measure of uncertainty in this prediction. This property is exploited by the
benchmark efficient global optimisation (EGO) algorithm,27 allowing the next point in the search to be chosen in
a way that formally balances the potential benefits of exploitation (searching around areas already known to be
promising) and exploration (searching in areas of high uncertainty). Although EGO was originally proposed for
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unconstrained optimisation of expensive objective functions with deterministic output, various proposals have
extended it to incorporate the expensive constraints,28 multiple objectives29 and stochastic outputs30 that feature
in complex SSD problems.
In this paper we will explore how GP regression models and a variant of the EGO algorithm can be used to
solve complex SSD problems. We will describe a general method which can be applied to almost any SSD
problem, providing the user can write a programme which simulates the data generating process and analysis
of the trial at any given set of parameter values and for a given choice of sample size, returning a binary indicator
denoting rejection or otherwise of the null hypothesis. By allowing user-written simulation programmes, we aim to
provide a flexible method which can be applied to a wide range of trial design problems. This approach will also
facilitate SSD for novel designs developed in the future and which cannot be anticipated now.
The remainder of the paper is structured as follows. A motivating example is described in section 2. In section
3, we provide the necessary background and notation regarding Monte Carlo estimation and multi-objective
optimisation. In section 4, we describe Gaussian process regression, the efficient global optimisation algorithm,
and a framework for its application to sample size determination. We return to the examples in section 5, illus-
trating how the method can be applied in practice, where we also conduct a simulation study. We conclude with a
discussion of the implications and limitations of the proposed approach in section 6.
2. Motivating example – PACE
‘Pacing, graded activity and cognitive behaviour therapy; a randomised evaluation’ (PACE)31,32 was a rando-
mised controlled trial comparing adaptive pacing therapy, cognitive behavioural therapy, graded exercise therapy
and specialist medical care as secondary care treatments for patients with chronic fatigue syndrome, with respect
to two potentially correlated continuous primary endpoints (fatigue and disability). Participants were randomised
to receive one of these four treatments, and we will henceforth refer to these randomised groups as ‘arms’ of the
trial. The data had a complex multilevel structure, with three of the four arms including a therapy provided by
different therapists (partially nested structure) and all arms including medical care from the same doctors (crossed
structure), leading to the potential for treatment-related clustering. Here, we consider how we might have designed
a pilot trial prior to the definitive PACE trial to provide a preliminary test of the potential efficacy of adaptive
pacing therapy (APT) in comparison to specialist medical care (SMC).
We assume the pilot trial would have the same complex multilevel data structure as the main trial, where
therapists are partially nested within interventions, doctors are crossed with interventions, and patients are cross-
classified with therapists and doctors in the intervention arm and nested within doctors in the control arm.33 This
structure is illustrated in Figure 1. As in the original PACE trial, the primary analysis will fit a mixed effect model
for each primary endpoint and use likelihood ratio tests to obtain a p-value in each case. By fitting separate
models for each endpoint, as opposed to a joint model, misspecification will be a potential problem if there are
correlations between the endpoints at the participant level, or between the random effects of therapists and
doctors. Such model misspecification has been noted as a clear motivation for simulation-based power calcula-
tions,3 which will allow an estimate of the true power, accounting for the effect of this misspecification, to be
obtained.
Figure 1. Multilevel structure of the SMC and APT arms of our example, where therapists (T) are partially nested within inter-
ventions, doctors (D) are crossed with interventions, and patients (P) are cross-classified with therapists and doctors in the inter-
vention arm and nested within doctors in the control arm.
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The results of the trial will be considered positive if either of the analyses show a statistically significant
difference, leading to an inflated type I error rate under the null hypothesis of no effect on each endpoint.34
This inflation, together with the small sample context, motivates the inclusion of the nominal type I error rate a as
a design parameter in this problem. Together with a, we have four further design parameters: the total sample size
in the APT arm, denoted n1; the number of APT therapists, k; the allocation ratio relating the total number of
participants in each arm, r ¼ n0=n1; and the number of doctors, j. Note that we assume we can control the
numbers of participants allocated to therapists and to doctors, and so can maximise efficiency by balancing
cluster sizes. The three objectives to be simultaneously minimised are the total number of participants, the
number of therapists, and the number of doctors. Finally, we have the two constraints of ensuring the actual
type I error rate is no more than 0.2 (one-sided), and the power is at least 90%. As both type I error rate and
power do not have analytical forms in this context, both constraints must be estimated using simulation.
3. Background
3.1. Monte Carlo estimation
Monte Carlo methods can be used to numerically approximate expectations E½fðZÞ of real valued functions f(Z)
with respect to the probability distribution of Z. Given a sample of N independent copies of Z, denoted zi,
i ¼ 1; . . . ;N, the MC estimate is
E½fðZÞ  1
N
XN
i¼1
fðziÞ (1)
The estimate is unbiased for all N and has variance equal to
x2 ¼ Var 1
N
XN
i¼1
fðziÞ
" #
¼ 1
N
Var fðziÞ½  (2)
The standard error of the MC estimate will therefore reduce at a rate of 1=
ffiffiffiffi
N
p
as we increase N. When N is
large we can consider an MC estimate to be the true expectation plus a normally distributed error term with 0
mean and variance x2, i.e.
1
N
XN
i¼1
fðziÞ ¼ E½fðZÞ þ ; where Nð0;x2Þ (3)
In the context of simulation-based trial design, if Z is the test statistic to be compared with an acceptance
region K then the probability of acceptance under hypothesis H is E½IðZ 2 KÞjH, where Ið:Þ is the indicator
function. An MC estimate of the power of a trial design under H can therefore be obtained given N test statistics
z1; . . . ; zN sampled under H. The steps required to simulate these statistics are described in Landau S and Stahl,
3
and we briefly summarise them here:
1. Define the population model. This describes the underlying target population and should specify all population
parameters and distributions under the hypothesis of interest.
2. Define the sampling strategy. This should specify the numbers of patients, clusters or any other sampling units
in the trial and how they will be drawn from the population.
3. Define the method of analysis. For hypothesis testing, this will include defining the form of the test statistic Z
and the acceptance region K.
Given each of the above elements, pseudo-random number generators can be used to simulate the recruitment,
randomisation and primary outcome measure of patients under the hypothesis of interest, from which a test
statistic zi can be calculated.
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3.2. Multi-objective optimisation
A solution to the SSD problem consists of a vector of design parameters x. The solution space X is the set of all
solutions. A simple SSD problem may have a one-dimensional solution space, while more complex problems may
have several dimensions. Elements of x may include parameters defining the sample size of the trial, the accep-
tance region to be used in the analysis, or any other design aspect over which we have control and which may
influence the trial operating characteristics. For instance, in a cluster randomised trial we could define a solution
by x ¼ ðk; nÞ, where k represents the number of clusters and n the number of participants in each arm.
An objective function fðxÞ is a function f : X ! R which we wish to minimise. In a multi-objective problem with
B objectives, we denote the vector of objective values as y ¼ ðf1ðxÞ; . . . ; fBðxÞÞ 2 RB. We will describe RB as the
objective space. Extending the cluster randomised trial example, we have two objectives: minimising the number of
clusters f1ðxÞ ¼ k; and minimising the total number of participants, f2ðxÞ ¼ 2n.
A constraint function gðxÞ is a function g : X ! R which must be less than or equal to 0 for the solution x to be
considered feasible. For example, if type II error rate is denoted by bðxÞ and the nominal type II error rate is set at
b, a constraint function would be gðxÞ ¼ bðxÞ  b. We denote C constraint functions as gjðxÞ; j ¼ 1; . . . ;C. The
general SSD problem can now be stated as
minx2X fiðxÞ; i ¼ 1; . . . ;B (4)
subject to gjðxÞ  0; j ¼ 1; . . . ;C (5)
We denote by  the relation of Pareto dominance, where a solution dominates another if it is at least as good in
all respects, and better in at least one. Formally, x  x if fiðxÞ  fiðxÞ for i ¼ 1; . . . ;B, and fjðxÞ < fjðxÞ for at
least one j. For instance, xa ¼ ðn ¼ 100; k ¼ 10Þ  xb ¼ ðn ¼ 120; k ¼ 10Þ in our cluster randomised trial example,
but xa ¼ ðn ¼ 100; k ¼ 10Þxc ¼ ðn ¼ 80; k ¼ 13Þ. The Pareto set is the set of non-dominated solutions
Xp ¼ fx 2 Xj@ x 2 X s:t: x  xg. An example Pareto set is plotted in Figure 2, illustrating the available
trade-offs between the objectives of minimising the number of clusters and number of participants in a
cluster trial.
Multi-objective optimisation seeks to find a set of solutions that are close to the true Pareto set, with every
member of the set non-dominated with respect to all other members. We will refer to these as approximation sets,
denoted A. That is, any set A 	 X such that fx 2 A : 9 x 2 A; x  xg ¼ 1 is an approximation set.29 A set A is
feasible if all constraints are satisfied by every member of A. An example feasible approximation set, plotted in
Figure 2, is given by the four ð2n; kÞ points
A ¼ fð589; 24Þ; ð705; 20Þ; ð810; 12Þ; ð982; 10Þg (6)
Figure 2. Example Pareto front X p and approximation set A for a cluster randomised trial design problem. The dominated
hypervolume of the approximation set with respect to a reference point (cross) is the shaded area.
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To understand the similarity between any approximation set A and the ideal Pareto set, we measure its
dominated hypervolume. This is the volume of the subspace dominated by solutions in A and bounded by a
reference point r
HðAÞ ¼ Volðfy 2 RBjy is dominated by some y 2 A and y  rgÞ (7)
The specific choice of r is not important, providing it is larger than anticipated worst-case objective values. The
largest possible hypervolume of any feasible approximation set A is achieved by the true Pareto set Xp. We can
therefore frame the multi-objective optimisation problem as finding the feasible approximation set A with largest
hypervolume. Taking a reference point of r ¼ ð1200; 30Þ (marked by the cross in Figure 2), our example approx-
imation set has a dominated hypervolume of 9202. This can be compared with that of the Pareto set, at 14501. We
would expect the approximation set to converge to the Pareto set as the number of optimisation iterations
increases.
4. Simulation-based sample size determination
4.1. Overview
The proposed method is based on the efficient global optimisation algorithm.35 For clarity, we will describe the
algorithm in the context of an SSD problem with a single constraint function, denoted gðxÞ, which must be
estimated using simulation. The more general case of several constraints will follow. The initial step is to select a
number of potential solutions to the SSD problem XE ¼ ðxð1Þ; . . . ; xðEÞÞ and evaluate the constraint function at
each of these points, giving yE ¼ ðgðxð1ÞÞ; . . . ; gðxðEÞÞÞ. A Gaussian process regression model is then fitted to the
data, relating the solutions XE to the estimates yE and providing an approximation of the constraint function g.
The solution x which has the largest expected improvement EIðxÞ according to the predictions of the GP model,
is then found. This solution is evaluated to obtain y. This new data is then used to update the GP model, which is
then used again to find the next solution to evaluate. The algorithm can be repeated until either the computational
resources available have been exceeded, or until no further improvements are being obtained. Algorithm 1 is
summarised below.
Figure 3. A Gaussian process model of a power function over a one-dimensional sample size (solid line) based on three evaluations.
Uncertainty is shown as the shaded area. Expected improvement (dotted line) is maximised at a sample size of 190, where the
predicted power is normally distributed around a mean estimate of 0.84 (dashed line).
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Algorithm 1 Efficient global optimisation35
1: Compute MC estimates yE ¼ ðgðxð1ÞÞ; . . . ; gðxðEÞÞÞ
2: While computation budget not exhausted do
3: Regress yE on XE ¼ ðxð1Þ; . . . ; xðEÞÞ
4: Find x ¼ argmaxEIðxÞ
5: Compute MC estimate y ¼ gðxÞ and add to yE; XE
6: Update the computational budget
7: End while
The process of computing MC estimates used in steps (1) and (5) has already been described in section 3.1.
In what follows we will first consider step (3), describing Gaussian process regression models and outlining how
they can be fitted and used to make predictions. The notion of expected improvement in step (4) will then be
defined for the constrained multi-objective problems we are concerned with. Finally, we cover the remaining
aspects of implementation.
4.2. Gaussian process regression
Consider a set of points XE ¼ fxð1Þ; . . . ; xðEÞg 	 X at which an expensive function g will be estimated using the
Monte Carlo method. Consider also some other point x 62 XE where we are interested in making a prediction of
gðxÞ. The value of g at each point in fXE; xg is initially unknown, but can be modelled by a Gaussian
process (GP).
In using a GP we assume that our belief regarding the values of g can be represented by a multivariate normal
distribution. Prior to computing any estimates of g, we assume that the mean function of this multivariate normal
is equal to zero.a We write the covariance matrix of the distribution as
KðXE;XEÞ KðXE; xÞ
Kðx;XEÞ Kðx; xÞ
 !
(8)
where KðXE;XEÞ is the E
E covariance matrix for the points XE; k ¼ KðXE; xÞ ¼ Kðx;XEÞ is the E-length
vector of covariances between XE and x and Kðx; xÞ is the variance at x.
Given this prior distribution, we compute the MC estimates yð1Þ; . . . ; yðEÞ at each point in XE. From equation
(3), yðiÞ ¼ gðxðiÞÞ þ ðiÞ where ðiÞ is a zero-mean normally distributed error term with standard deviation xðiÞ. We
denote by D the E
E diagonal matrix where the ith entry is ½xðiÞ2. The distribution of gðxÞ conditional on the
observed y can be shown to be normal with mean k> ðKþ DÞ1y and variance kðx; xÞ  k> ðKþ DÞ1k.25 Thus,
given a prior covariance matrix of the form (8) and some MC estimates of g at the points XE, a conditional
predictive distribution of gðxÞ can be found. It is this distribution which will be used in the optimisation algo-
rithm when deciding which solution should next be evaluated.
The predictive distributions are influenced by the prior covariance matrix (8). The matrix is populated using a
covariance function (or kernel), kðx; x0Þ : X 
 X ! R. This function must be symmetric and positive definite for
the covariance matrix to have the same properties. One such covariance function is the squared exponential,
which has the form
kðx; x0Þ ¼ rexp 
XD
j¼1
ðxj  x0jÞ2
k2j
0
@
1
A (9)
By using covariance functions of this form we will obtain a Gaussian process which is infinitely differentiable
over X and thus very smooth. This would appear to be a reasonable restriction to place upon the power functions
we are interested in. In order to populate the covariance matrix we must choose values of the hyperparameters
h ¼ ðr; k1; . . . ; kDÞ. We do this by numerically optimising the log marginal likelihood
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logpðyjXE; hÞ ¼  1
2
y>½Kþ D1y 1
2
logjKþ Dj  n
2
log2p (10)
considered as a function of h.25 Fitting a GP model by maximum likelihood in this manner can be done using the
function km in the R package DiceKriging, as illustrated in the supplemental material.
An illustration of a Gaussian process regression model of a power function in one dimension is given in
Figure 3. The power of three different choices of sample size has been calculated and a GP model fitted to the
results. The figure illustrates how the uncertainty in the model predictions (shaded area) increases the further we
are from a point which has been evaluated. The GP prediction of power at a sample size of n¼ 190, shown as a
dashed line, is normally distributed with mean 0.84 and standard deviation 0.035.
4.3. Expected improvement
At any given point during the optimisation process we can obtain an approximation set A based on the set of
solutions which have been evaluated up to that point. If a new point x is considered feasible, a new approxi-
mation set A will be identified. The improvement resulting from the evaluation of x is the difference in the
dominated hypervolumes
I ¼ HðAÞ HðAÞ (11)
Prior to evaluation, we do not know if the point x will be considered feasible. We therefore modify I to
account for the probability that x will be considered feasible after the MC estimates have been obtained. This
probability can be estimated using the GP regression methodology described in section 4.2. A GP model of
unknown constraint function g will describe our current belief about the value of g at x using a normal distri-
bution with mean m and variance s2 gðxÞN ðm; s2Þ, and we will consider the point x feasible if the upper
100
 p% quantile of this distribution is below 0. We denote this quantile as
qðxÞ ¼ mþ U1ðpÞs (12)
where U is the standard normal cumulative distribution. Following an evaluation of x the GP model will be
updated and the quantile revised to qþðxÞ. Before the evaluation the value of qþðxÞ is unknown, but it is shown
in Picheny and Ginsbourger30 that its predictive distribution is qþðxÞNðmþ; s2þÞ where
mþ ¼ mþ U1ðpÞ
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
x2s2
x2 þ s2
s
(13)
s2þ ¼
½s22
x2 þ s2 (14)
and x is the MC error of the planned evaluation, estimated as mð1mÞ=N where N is the number of MC samples
to be used. The predictive distribution can then be used to calculate the probability that the point x will be
considered feasible following its evaluation. Following Sasena et al.,28 we multiply the theoretical improvement I
by this probability, thus penalising candidate solutions with a low chance of satisfying the constraint. This then
gives us our expected improvement measure EI, where
Expected Improvement EIðxÞ ¼ ½HðAÞ HðAÞ
YC
j¼1
U
mj;þ
sj;þ
 
(15)
Note that we include a penalty term for all j ¼ 1; . . . ;C constraint functions. This maximisation problem is in
itself complex, with a potentially large number of local maxima. We therefore use the particle swarm optimisation
algorithm as implemented in the R package pso,36 designed to avoid becoming trapped in local maxima, to solve
this sub-problem.
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An illustration of expected improvement for a single-objective problem is given in Figure 3. When choosing
which sample size to evaluate next and aiming to find the lowest per-arm sample size with at least 80% power, we
balance the potential improvement over the best current solution (a sample size of 260) with the probability of
constraint satisfaction. In this case, we would choose to evaluate the sample size of 190, estimated by the GP
model to have a power of 84%.
4.4. Fixed space-filling design
An alternative to the EGO algorithm is to evaluate a number of solutions chosen using a space-filling experi-
mental design, and use these to construct an approximation set. Specifically, we construct a Sobol sequence (a
low-discrepancy sequence which can be thought of as a quasi-random uniform distribution) and estimate the type
II error rate at each of these solutions using NMC samples. For each point a confidence interval based on the MC
error can then be calculated, and any points where the interval was not entirely below the nominal value
discarded. Of those that remained, any dominated solutions are discarded to leave an approximation set. We
will refer to this as the ‘fixed design’ method.
4.5. Implementation
To apply Algorithm 1 in practice we must first choose the initial set of points to be evaluated, XE. One recom-
mendation is to use a space-filling design with 10 points for each dimension of the solution space, and to allocate
between 30% and 50% of the total computation budget to their evaluation.37 To select the location of the points in
XE we use the space-filling Sobol sequence generated using the R package randtoolbox.38 The number of iterations
and the number of MC samples N used at each iteration must also be chosen. Given a total computational budget in
terms of MC samples, the choice of these values should account for the fact that fitting GP regression models in R to
more than around 800 points is currently infeasible.39 The choice of the computational budget itself is not critical
since, after terminating the algorithm, it can be simply restarted from its final state. This may be sensible if, for
example, the trajectory of solution quality does not appear to have plateaued at termination.
As the algorithm depends on GP regression models, it can be helpful to assess the fit of these models. One
approach is to regularly plot the predicted mean and standard deviation in one or two dimensions, centred at the
last evaluated point. Poor model fit could be identified if the mean function is not, for example, strictly increasing
as expected. We can also contrast the predicted function values with the obtained function values at each iteration,
halting the algorithm if a large and unexpected discrepancy in these values is observed.
We have implemented the proposed framework in R, partly due to the availability of robust and efficient R
packages for fitting Gaussian process models (DiceKriging26) and for global optimisation (pso36). Using R also
provides flexibility in terms of the user-written simulation routines by facilitating various complicated analysis
procedures, e.g. multilevel modelling through lme4.40 The implementation is provided in the supplementary
material and online at https://github.com/DTWilson/Bayes_opt_SSD, where we show how it can be applied to
solve a number of example SSD problems.
5. Illustration and evaluation
5.1. Application to a hypothetical example
We begin by showing how the proposed method can be applied to design a hypothetical two-arm cluster rand-
omised trial with a continuous, normally distributed outcome, k clusters in each arm, and m participants in each
cluster. The outcome of participant i in cluster j is modelled as
yij ¼ b0 þ b1ti þ uj þ ei (16)
ujNð0; r2BÞ (17)
eiNð0; r2WÞ (18)
where ti¼ 1 if patient i is in the intervention arm, and ti¼ 0 otherwise. The trial will be analysed using a two-
sample t-test comparing the cluster sample means
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yj ¼
1
m
Xm
i¼1
yij
in the two arms. We assume the nuisance parameters are known and equal to r2W ¼ 0:95; r2B ¼ 0:05.
To apply the proposed method, we define k and n ¼ m  k as design parameters and search over the ranges
k 2 ½10; 100 and n 2 ½100; 500. We wish to minimise the two objectives f1ðxÞ ¼ 2n (the total number of partic-
ipants) and f2ðxÞ ¼ 2k (the total number of clusters). Fixing the type I error rate at 0.025 (one-sided), we can then
use simulation to estimate the type II error rate and find an approximation set of solutions which give a value no
more than the nominal 0.1. We initialised the optimisation algorithm by generating a Sobol sequence of size 20
and computing MC estimates of power for each point using N¼ 100 samples. Following this, 30 iterations of the
algorithm were applied, with N¼ 100 samples used at each iteration. To explore the effect of increasing the
computational budget, we then continued with another 150 iterations of the algorithm. For comparison, we
found an alternative approximation set using the approach of section 4.4, evaluating 50 solutions in a fixed
space-filling design. Finally, we note that in this example power can be calculated analytically (by noting that
the variance of the cluster means will equal r2B þ r2W=m), and so we can find the true Pareto set and compare the
three approximation sets against it.
In Figure 4, we plot the 50 solutions evaluated over the course of the EGO algorithm, distinguishing between
those in the initial design XE, those which were subsequently evaluated during the iterative phase of the algorithm,
and those which together form the final approximation set. The contours of the mean function of the final GP
model are also shown. We also plot the approximation front obtained using the comparator approach, the true
Pareto set, and the approximation set obtained by running a further 150 iterations of the EGO algorithm.
We find that the EGO algorithm leads to a much better approximation set than the comparator, for the same
computation budget. For example, the fixed design method suggests that in order to limit the number of clusters
to 80, a total of 988 participants will be required. In contrast, the EGO method shows that a total sample size of
only 766 is needed. The true minimal sample size required for 80 clusters is 649 participants, showing that while
the EGO algorithm can substantially improve upon the simpler alternative, it has still suggested an approximation
set that is some distance from the Pareto set. As shown in Table 1, all the suggested solutions are adequately
powered with a true type II error rate b less than the nominal 0.1. Increasing the computational budget by
applying a further 150 iterations of the algorithm moves the approximation set closer to the Pareto set, as
would be expected.
5.2. Simulation study
To understand the variability in performance of the proposed method, we conducted a simulation study based on
the preceding hypothetical example in section 5.1. We applied the method as before, with 20 initial evaluations at
points determined by a Sobol sequence, followed by 30 iterations of the algorithm. At each evaluation, N¼ 100
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Figure 4. Objective values of solutions in the initial set XE (open circles), subsequent iterations of the algorithm (crosses), and those
in the final approximations of the Pareto set (filled circles). The approximation sets are obtained using the EGO algorithm for 50 and
200 evaluations, and using a fixed design of size 50). Contours represent the mean function of the final GP model.
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MC samples were used when estimating power. We repeated this process 500 times. For comparison, we also
applied the fixed design approach by evaluating 50 solutions chosen by a Sobol sequence, discarding those with an
estimated type II error rate greater than the nominal 0.1, and finding the approximation set from the remaining
solutions. We repeated this process 500 times, again using N ¼ 100 MC samples at each evaluation. We then
extended the fixed design from size 50 to size 200, 400, 600, 800 and 1000. For each approximation set obtained,
we recorded the dominated hypervolume and the number of solutions it contains. We also calculated the true type
II error rate for each solution, and recorded the proportion of solutions in the approximation set which had a true
type II error rate no more than the nominal 0.1.
We plot the distribution of the dominated hypervolumes in Figure 5. Comparing the EGO and fixed design
methods when each uses 50 evaluations in total, we find that the average dominated hypervolumes are 4824 and
3243, respectively. There is some overlap in the distributions. For example, 92% of EGO runs led to a dominated
hypervolume greater than 4500, compared with 1% of fixed design runs. Increasing the number of evaluations in
the fixed design improves the solution quality as expected, but to obtain an average performance similar to the
EGO algorithm the number of evaluations must be increased to between 800 and 1000.
Figure 5 shows that the approximation sets are typically larger than those obtained using fixed designs, with an
average of 10.9 solutions. In comparison, a fixed design of size 50 had an average of 4.4. This suggests that as well
as producing approximation sets of consistently higher quality, the EGO approach will also provide more choice
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Figure 5. Distributions of dominated hypervolumes (left) and size (right) of approximation sets obtained using the EGO method and
the fixed design method. The dashed horizontal line on the left hand plot indicates the dominated hypervolume of the true Pareto set.
Table 1. Approximation sets for the hypothetical example obtained using the EGO algorithm and the fixed design approach, with 50
evaluations each. Solutions are defined by the total number of participants, 2n, and the total number of clusters, 2k. The true type II
error rate b is shown alongside with the estimate b̂ obtained using N¼ 100 MC samples.
EGO Fixed design
2n 2k b̂ (s.e.) b 2n 2k b̂ (s.e.) b
834 68 0.06 (0.026) 0.073 988 80 0.04 (0.019) 0.039
806 74 0.07 (0.025) 0.070 924 94 0.05 (0.019) 0.036
766 78 0.11 (0.026) 0.073 862 108 0.05 (0.019) 0.036
750 84 0.10 (0.026) 0.070 788 124 0.03 (0.02) 0.040
708 94 0.06 (0.026) 0.071 724 138 0.02 (0.021) 0.047
650 98 0.13 (0.028) 0.083 662 152 0.05 (0.023) 0.056
632 106 0.07 (0.028) 0.083 638 158 0.05 (0.024) 0.061
612 118 0.07 (0.028) 0.083
596 136 0.07 (0.027) 0.080
588 146 0.08 (0.027) 0.080
EGO: efficient global optimisation.
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for trading off the two conflicting objectives. The vast majority (98%) of EGO approximation sets contained only
valid solutions with a true type II error rate of at most 0.1. For the fixed design method, this proportion was
similar when 50 solutions were evaluated but decreased as the number of evaluations increased. For fixed designs
of size 1000, 63% of approximation sets contained at least one invalid solutions, although there were at most three
invalid solutions in any one approximation set.
We also investigated the effect of changing E, the number of solutions evaluated initially before the iterative
part of the EGO algorithm. Keeping the total number of evaluations at 50, we considered E¼ 10 and 30 in
addition to the case E¼ 20 already presented. As before, the algorithm was run 500 times and the dominated
hypervolume of the final approximation set was recorded. We found little difference between setting E¼ 10 (mean
4823) and E¼ 20 (mean 4824). When the number of initial evaluations was increased to E¼ 30, we found a
statistically significant decrease in the mean dominated hypervolume to 4761. We can therefore conclude that, in
this example, the recommendations referenced in section 4.5 (setting E to ten times the dimensions of the solutions
space and representing 30% to 50% of the total computational budget) work well.
5.3. Application to the motivating example
Recall that the PACE trial measured two primary endpoints, one relating to fatigue (denoted as F) and one to
disability (denoted as D). Our model of the continuous response of the ith participant for endpoint r 2 fF;Dg can
be written, using the multilevel model notation of Goldstein,41 as
yri ¼ br0 þ br1ti þ urtherapistðiÞti þ vrdoctorðiÞ þ eri (19)
Correlation between the two endpoints is modelled by simulating bivariate residuals ðeFi ; eDi Þ from a joint
normal distribution with correlation qW and marginal variances r2W. We also allow for correlation between
the random effects associated with each therapist and doctor. These are simulated according to the bivariate
normal distributions
ðuFtherapistðiÞ; uDtherapistðiÞÞN ð0; 0ÞT;
r2T qTr
2
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T r
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For the purposes of power calculations we must make some assumptions about the various nuisance parameter
values. We set the second level variance components to r2T ¼ 0:19; r2D ¼ 0:37 and r2W ¼ 3:29 in order to give a
variance partition coefficient of r2D=ðr2D þ r2WÞ ¼ 0:1 in the control arm, a typical value in this setting. Similarly,
the variance partition coefficient for between-therapist variance is then r2T=ðr2T þ r2D þ r2WÞ ¼ 0:05, and for
between-doctor variation, r2D=ðr2T þ r2D þ r2WÞ ¼ 0:095. We set all correlations equal at qW ¼ qT ¼
qD ¼ qD ¼ 0:9, reflecting a situation where both a patient’s responses and the individual therapist and doctor
effects and very similar for both the fatigue and disability outcomes. We want to simulate the power of the trial
under the alternative hypotheses H1 : b1 ¼ 1:10. Note that this corresponds to a treatment effect standardised
with respect to the total standard deviation in the intervention arm of 1:10=
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffið0:19þ 0:37þ 3:29Þp ¼ 0:56.
Our design parameters (together with the ranges considered) are the total sample size in the intervention arm,
denoted n1 (50 to 100); the number of therapists, k (2 to 10); the allocation ratio relating the total number of
participants in each arm, r ¼ n0=n1 (0.5 to 1.5); the number of doctors, j (3 to 20); and the nominal type I error
rate to be used in the hypothesis tests, a (0.05 to 0.2). The three objective functions to be minimised are f1ðxÞ ¼
n1 þ rn1; f2ðxÞ ¼ k and f3ðxÞ ¼ j. The two constraints to be satisfied are g1ðxÞ ¼ bðxÞ  0:1 and g2ðxÞ ¼ aðxÞ  0:2.
We initialised the algorithm by generating a Sobol sequence of size 50 and computing MC estimates of power
for each point using N¼ 100 MC samples. After 150 iterations of the algorithm, an approximation set containing
12 solutions was obtained. The algorithm took 2 h and 36min to run on a PC with a 2.60GHz processor and 8GB
RAM. The objective values of these solutions are illustrated in Figure 6, with full details provided in Table 2. The
total number of participants ranged from 140 to 214; of therapists, from 5 to 10; and of doctors, from 5 to 23.
Nominal type I error rates ranged from 0.09 to 0.14, all some way below the actual constraint value of 0.2. We
calculated precise MC estimates (using N ¼ 504 samples) of both type I and II error rates for each solution in the
approximation set. As shown in Table 2, type II error rates all appear to be around or slightly below the constraint
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of 0.1. This demonstrates the GP’s ability to share information of MC estimates computed at several points to
increase the precision at each of them. Type I error rates, in contrast, are in some cases significantly below the
constraint of 0.2. This suggests there is some potential for improvement in the approximation set by applying
further iterations of the algorithm. For comparison, we use the fixed design approach, evaluating 200 solutions,
but found that all of these had a type I or II error rate beyond their respective constraints.
6. Discussion
Although simulation is often required for clinical trial sample size determination, related methodology has typ-
ically assumed that there is only one parameter which we are able to adjust (the sample size); that there is only one
operating characteristic which must be estimated using simulation (the power of the trial); and that our goal is to
minimise only one criterion (the sample size again).3,5 In this paper, we have described a flexible approach to
simulation-based SSD, which can be used for more general multi-parameter problems. The method draws on
established global optimisation algorithms, which use statistical ‘surrogate’ models to solve design problems
where there are several parameters to be chosen, several objectives to minimise, and several constraints to satisfy.
We have illustrated how such problems arise in clinical trials of complex interventions.
The general optimisation framework we have suggested recognises that in many complex trials we are inter-
ested in minimising more than one quantity subject to constraints on operating characteristics. Problems of this
Table 2. Approximation set after 50 iterations for the motivating example. Solutions are defined by the number of participants in the
APTarm n1, the total number of participants across both arms n, the number of therapists k, the number of doctors j and the nominal
type I error rates a. Both type I and II error rates are estimated using simulation using N samples, and are constrained at 0.2 and 0.1,
respectively.
N ¼ 102 N ¼ 504
n1 n k j a b (s.e.) a (s.e.) b (s.e.) a (s.e.)
94 202 5 15 0.11 0.07 (0.026) 0.12 (0.033) 0.088 (0.003) 0.17 (0.004)
94 169 6 21 0.12 0.11 (0.031) 0.13 (0.034) 0.081 (0.003) 0.179 (0.004)
94 214 6 12 0.11 0.05 (0.022) 0.21 (0.041) 0.09 (0.003) 0.157 (0.004)
84 167 6 23 0.10 0.09 (0.029) 0.12 (0.033) 0.103 (0.003) 0.147 (0.004)
79 174 7 10 0.12 0.17 (0.038) 0.13 (0.034) 0.086 (0.003) 0.171 (0.004)
95 203 7 9 0.09 0.1 (0.03) 0.16 (0.037) 0.085 (0.003) 0.134 (0.003)
75 152 8 9 0.13 0.1 (0.03) 0.12 (0.033) 0.083 (0.003) 0.175 (0.004)
78 149 8 16 0.12 0.08 (0.027) 0.21 (0.041) 0.088 (0.003) 0.171 (0.004)
76 142 8 22 0.12 0.07 (0.026) 0.17 (0.038) 0.098 (0.003) 0.156 (0.004)
80 140 9 17 0.13 0.04 (0.02) 0.2 (0.04) 0.084 (0.003) 0.176 (0.004)
81 146 9 12 0.14 0.14 (0.035) 0.18 (0.039) 0.079 (0.003) 0.181 (0.004)
97 190 10 5 0.14 0.07 (0.026) 0.27 (0.045) 0.072 (0.003) 0.178 (0.004)
5
6
7
8
9
10
140 160 180 200
Number of participants
N
um
be
r 
of
 th
er
ap
is
ts
No. of doctors
5
10
15
20
Figure 6. Objective values of the approximation set obtained following 50 iterations of the algorithm for the motivating example.
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sort are common in multilevel trial design,42 but are typically approached by first reducing the multiple objectives
down to a single objective. For example, in the design of a cluster randomised trial it is common to fix the number
of participants per cluster and minimise the number of clusters,43 or vice-versa.44,45 Alternatively, a function that
specifies the cost of sampling at the cluster and the patient level could be specified,46 and the overall cost could be
minimised.47 The latter approach has been suggested for both two-level48 and three-level hierarchical trial
designs.49,50 However, the a priori specification of such a cost function may not always be feasible, particularly
when several stakeholders are involved.51 The Pareto optimisation framework we have described leads to a more
computationally challenging optimisation problem, but produces a set of good solutions enabling the available
trade-offs between objectives to be seen and selected from.
As noted in section 1, related work in simulation-based design methodology has often focussed on a specific
area of application. One advantage that brings is the relative ease with which the software can be used to solve a
new problem within the same area. In contrast, our approach requires that the user provides a programme which
simulates the data generation and analysis of their proposed trial design. Although some have argued that this
requirement may be prohibitive in practice,18 it allows the user to solve their specific problem rather than some
related version of it. Moreover, prior to addressing the sample size issue, modelling and simulation can help
inform many other aspects of trial design, such as the patient population or the choice of endpoint.52 One way to
assist users in writing their own simulations is to share example programmes for a range of problems, providing a
starting point for the development of a new programme. We have provided some examples in the supplemental
material.
When submitting a proposed design for approval by a funding body it is important that the sample size
calculation is transparent and replicable. This may be achieved in the context of simulation-based SSD by sup-
plying the simulation programme as part of the application.5 Given this, any reviewer should be able to re-
calculate the operating characteristics of the proposed design. However, a greater challenge for the reviewer is
understanding the programme and ensuring it is an accurate representation of the model in question. This
requirement has partly motivated our use of R. Although significantly slower than a compiled language such
as Cþþ, it has been argued that software written in R is more transparent.52 Validation will be further facilitated
if a simulation protocol of the sort described in Burton et al.53 is provided alongside the code. Future work could
develop an interface for alternative statistical software such as Stata or SAS, allowing a simulation programme to
be written in them and connect with the R implementation of the optimisation algorithm.
We have followed the conventional approach to clinical trial design whereby constraints on operating char-
acteristics are set and then a constrained optimisation problem is solved. In practice the constraints are not fixed
in advance, but adjusted iteratively in response to the design requirements they produce. For example, an initial
nominal power of 90% may require an infeasibly large sample size, leading to a revision down to 80%. Such an
iterative procedure will increase an already substantial computational burden for simulation-based design.
However, note that a change to a constraint does not mean starting the process again, since any previous MC
estimates can still be used when fitting the GP model(s). The sequential nature of the optimisation algorithm
suggests that an interactive routine could be developed, where the user pauses the algorithm in response to the
sample size requirements which are being observed, adjusts the constraints, and then continues with the
optimisation.
We have defined power in relation to a specific value of the parameter of interest, the so-called MCID, and
specific point estimates of any nuisance parameters. Implicit in this formulation is an assumed monotonicity of the
power function with respect to the parameter of interest. That is, we assume that if the power at this point is above
the nominal constraint, then power at all larger values will also be above this level. When this assumption cannot
be made, the method could be applied by setting further power constraints at other points in the parameter space.
This approach could also be taken with respect to any nuisance parameters, helping to guard against any error in
their estimation. This will, however, increase the computational burden by requiring more simulations at each
iteration of the algorithm.
The examples have demonstrated that the time required to solve a sample size determination problem can be
significant, of the order of hours. Given that the majority of computational effort is expended generating MC
samples when evaluating solutions, it is important that these simulation programmes are as efficient as possible.
We recommend making use of code profilers such as R’s ‘Rprof’ to identify the parts of the programme that are
consuming the most resources. Further efficiencies could potentially be gained by using more sophisticated
methods for surrogate modelling and efficient optimisation. For example, prior knowledge such as the power
function being bounded or monotonic could be incorporated into the surrogate modelling process.29
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Numerous extensions to the proposed approach can be considered. One argument for simulation-based
design is the ease with which sensitivity to model assumptions, such as the value of nuisance parameters, can be
assessed.3 Future work could consider how a systematic assessment of sensitivity to nuisance parameters could
be conducted, given a proposed trial design. Such investigations fall under the heading of uncertainty quan-
tification and can be carried out using GP regression and associated techniques.54 A further extension could
consider Bayesian approaches to trial design, including hybrid Bayesian-frequentist assurances,55 fully
Bayesian measures such as average coverage criterion56 and decision-theoretic methods.57 Aside from very
simple cases involving only conjugate analyses, evaluating these Bayesian criteria will generally require sim-
ulation55 and so optimal design may benefit from the efficient methods discussed here. Complex SSD problems
are also common in the area of adaptive designs, which can aim to minimise the expected sample size under
several different hypotheses and over a number of stopping rule parameters.19 Extending the proposed meth-
ods to such problems would require using surrogate models to approximate the objective functions, as opposed
to only the constraints.
In conclusion, efficient optimisation algorithms based on surrogate models of expensive operating character-
istic functions can be used to solve complex clinical trial sample size determination problems. By using these
methods we can avoid making unrealistic simplifying assumptions at the trial design stage, both in terms of the
statistical model underlying the trial and of the nature of the design problem.
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Note
a. This is not a restrictive assumption. After observing estimates of the function g and updating the GP model to account for
these, the mean function can take on non-zero values.
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